Whalen Wealth Management Inc. Makes New Investment in Elanco Animal Health Incorporated $ELAN

Whalen Wealth Management Inc. acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 21,814 shares of the company’s stock, valued at approximately $537,000.

Several other hedge funds have also made changes to their positions in ELAN. BlackRock Inc. acquired a new position in Elanco Animal Health in the second quarter valued at $1,202,198,000. UBS Group AG boosted its stake in Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after buying an additional 5,961,457 shares during the last quarter. Sei Investments Co. boosted its stake in Elanco Animal Health by 737.5% in the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after buying an additional 4,975,721 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Elanco Animal Health by 11.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after buying an additional 3,717,404 shares during the period. Finally, Invesco Ltd. grew its holdings in Elanco Animal Health by 336.0% in the 4th quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock valued at $108,376,000 after buying an additional 3,690,735 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

ELAN stock opened at $24.41 on Tuesday. The company has a market cap of $12.20 billion, a PE ratio of -59.54, a price-to-earnings-growth ratio of 1.44 and a beta of 1.67. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The stock has a 50-day moving average price of $24.56 and a two-hundred day moving average price of $24.00. Elanco Animal Health Incorporated has a 12-month low of $17.11 and a 12-month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, research analysts predict that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Michael J. Harrington acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was bought at an average cost of $21.82 per share, for a total transaction of $109,100.00. Following the completion of the purchase, the director directly owned 131,451 shares in the company, valued at $2,868,260.82. This represents a 3.95% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Lawrence Erik Kurzius acquired 40,000 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was acquired at an average cost of $23.40 per share, with a total value of $936,000.00. Following the transaction, the director directly owned 188,647 shares of the company’s stock, valued at approximately $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 63,198 shares of company stock valued at $1,473,109 in the last three months. 1.14% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ELAN. Morgan Stanley increased their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. JPMorgan Chase & Co. boosted their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. TD Cowen upped their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Finally, KeyCorp increased their price target on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.